Table 1.
Characteristics of birth cohort veterans tested for HCV
| Characteristics | N (% overall) | % Tested for HCV | % of overall HCV Ab +ve | % of overall HCV RNA +ve |
|---|---|---|---|---|
| Overall | 4,221,135 | 51% | 8.1% | 5.4% |
| ○ Year of birth: | ||||
| • 1945-1949 | 1,683,073 (39.9%) | 53% | 6.0% | 3.7% |
| • 1950-1954 | 1,002,366 (23.7%) | 53% | 11.9% | 8.5% |
| • 1955-1959 | 794,945 (18.8%) | 51% | 10.8% | 7.7% |
| • 1960-1965 | 740,751 (17.5%) | 43% | 4.5% | 2.5% |
| ○ Sex: | ||||
| • Male | 3,726,077 (88.3%) | 53% | 8.7% | 5.9% |
| • Female | 495,058 (11.7%) | 35% | 3.0% | 1.5% |
| ○ Race: | ||||
| • American Indian/Alaska Native | 29,661 (0.7%) | 52% | 7.9% | 5.9% |
| • Asian | 26,192 (0.6%) | 50% | 2.6% | 1.6% |
| • Black/African American | 666,983 (15.8%) | 62% | 14.7% | 10.5% |
| • Native Hawaiian/Pacific Islander | 45,957 (1.1%) | 59% | 8.7% | 6.0% |
| • Declined to Answer/Unknown | 1,141,956 (27.1%) | 35% | 5.1% | 3.3% |
| • White | 2,310,386 (54.7%) | 55% | 7.6% | 5.0% |
| ○ ALT: | ||||
| • ≤40 | 2,631,683 (56.1%) | 57% | 6.5% | 3.2% |
| • >40 | 880,511 (20.2%) | 67% | 18.8% | 16.1% |
| • Not done or missing | 708,941 (16.8%) | 5% | 0.5% | 0.2% |
| ○ FIB-4: | ||||
| • <1.45 | 2,369,163 (56.1%) | 58% | 6.8% | 3.3% |
| • 1.45-3.25 | 852,230 (20.2%) | 63% | 12.6% | 9.3% |
| • >3.25 | 186,697 (4.4%) | 80% | 33.8% | 30.5% |
| • Missing values | 813,045 (19.3%) | 9% | 0.9% | 0.5% |
| ○ APRI: | ||||
| • ≤0.5 | 2,933,008 (69.5%) | 58% | 6.5% | 3.3% |
| • >0.5-<1.5 | 401,323 (9.5%) | 73% | 28.4% | 20.7% |
| • ≥1.5 | 102,958 (2.4%) | 84% | 45.6% | 42.8% |
| • Missing values | 783,846 (18.6%) | 9% | 0.8% | 0.4% |
| ○ HIV Status | ||||
| • Positive | 25,059 (0.6%) | 84.1% | 31.9% | 27.1% |
| • Negative | 4,196,076 (99.4%) | 50.5% | 7.9% | 5.3% |
| ○ HBV Status | ||||
| • Positive | 384,470 (9.1%) | 85.8% | 34.4% | 26.9% |
| • Negative | 3,836,665 (90.9%) | 47.2% | 5.4% | 3.2% |
| ○ Visits | ||||
| • Q1# (<=13) | 1,097,384 (26.0%) | 24% | 2.8% | 1.3% |
| • Q2 (14-44) | 1,022,102 (24.2%) | 47% | 5.9% | 3.5% |
| • Q3 (45-113) | 1,032,887 (24.5%) | 60% | 9.2% | 6.1% |
| • Q4 (>113) | 1,068,762 (25.3%) | 72% | 14.4% | 10.8% |
Q1-4: Quartiles; FIB-4, APRI calculations detailed in Methods, HIV: Human Immunodeficiency virus, HBV: Hepatitis B virus